BRUSSELS, Belgium, October 3, 2007 – Thalidomide was introduced as a sedative in Europe and Canada in the late 1950s, and was widely used to treat insomnia and nausea during pregnancy.
BRUSSELS, Belgium BRUSSELS, Belgium, June 29 -- The European Myeloma Platform (EMP) says updated data for previously treated patients on REVLIMID (lenalidomide) plus the steroid dexamethasone show median survival of 35 months, nearly three years.
Brussels, Belgium – (June 20, 2007) – The European Myeloma Platform (EMP) applauds the EMEA decision to grant marketing authorization for REVLIMID (lenalidomide) for the treatment of patients with multiple myeloma who have received at least one prior therapy.
New Clinical Data Reports 100% Response Rate for Elderly Patients, After Two-Years of Follow-up
On March 22, 2007, the EMEA (European Medicines Agency), in its scientific committee CHMP (Committee for Medicinal Products for Human Use), has issued a positive opinion recommending the marketing authorisation for Revlimid.